Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
Our lead program, ADCETRIS® (brentuximab vedotin), is the first in a new class of ADCs. In collaboration with Takeda Pharmaceutical Company Limited, it is commercially available in 65 countries. To further expand the ADCETRIS opportunity, we are conducting a broad clinical development program evaluating its potential to become the foundation of treatment for CD30-expressing lymphomas.
We also are advancing vadastuximab talirine (SGN-CD33A; 33A), a novel ADC in the pivotal CASCADE trial for acute myeloid leukemia (AML). AML is a significant unmet need, as AML treatments have not meaningfully changed in more than three decades.
ADCETRIS and 33A are two of more than 20 ADCs in clinical development using our proprietary technology. We are also advancing enfortumab vedotin (ASG-22ME) under our collaboration with Astellas, as well as several other internal clinical and preclinical programs. Our deep product pipeline provides opportunities across hematologic malignancies and solid tumors.
Our ADC technology also is employed by collaborators who are advancing multiple programs using Seattle Genetics’ proprietary approach to empowering antibodies. Through internal research and development, collaborations and scientific innovation, we are committed to improving treatment outcomes for patients.